EBS Key Stats
|Revenue (Quarterly YoY Growth)||33.80%|
|EPS Diluted (TTM)||0.8724|
|EPS Diluted (Quarterly YoY Growth)||100.0%|
|Net Income (TTM)||32.02M|
|Gross Profit Margin (Quarterly)||77.48%|
|Profit Margin (Quarterly)||15.14%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- Notable Mergers and Acquisitions of the Day 12/12: (UNS) (XLS) (MKTO) (EBS) Street Insider 10:09 AM
- Emergent Bio (EBS) to Acquire Cangene Corp in $222M Deal Street Insider 6:46 AM
- 7:04 am Emergent BioSolutions shows positive results in combination with rituximab in people with CLL; Otlertuzumab was well tolerated in Cohort 1. 54% of patients experienced infusion reactions Dec 10
- EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 10
- Emergent BioSolutions' Otlertuzumab (TRU-016) Shows Positive Results in Combination with Rituximab in People with CLL noodls Dec 10
- Emergent Bio (EBS) Issues Encouraging Update on TRU-016 Phase 1b in CLL Patients Street Insider Dec 10
- Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab (TRU-016) in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia noodls Dec 9
- Emergent BioSolutions to Webcast Presentation at the 32nd Annual J.P. Morgan Healthcare Conference Business Wire Dec 2
- Emergent BioSolutions Appoints A.B. Cruz III as Executive Vice President and General Counsel noodls Nov 26
- Emergent BioSolutions to Webcast Its Participation at the 25th Annual Piper Jaffray Healthcare Conference noodls Nov 20
EBS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Emergent BioSolutions is up 44.75% over the last year vs S&P 500 Total Return up 27.09%, Targacept up 13.35%, and Jazz Pharmaceuticals up 128.1%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for EBS
Pro Report PDF for EBS
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download EBS Pro Report PDF
Pro Strategies Featuring EBS
Did Emergent BioSolutions make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Emergent BioSolutions, Inc. is a biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body’s immune system to prevent or treat disease.